HIV entry blocker pairs CD4 mimic and antibody, showing sevenfold higher efficacy

HIV entry blocker pairs CD4 mimic and antibody, showing sevenfold higher efficacy

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry—offering seven times better efficacy than existing approaches. Overall, the findings point towards a promising new direction for HIV treatment—targeting …